Gary Dubin

17.6k total citations · 5 hit papers
74 papers, 8.5k citations indexed

About

Gary Dubin is a scholar working on Epidemiology, Immunology and Surgery. According to data from OpenAlex, Gary Dubin has authored 74 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 18 papers in Immunology and 15 papers in Surgery. Recurrent topics in Gary Dubin's work include Hepatitis B Virus Studies (43 papers), Cervical Cancer and HPV Research (41 papers) and Herpesvirus Infections and Treatments (19 papers). Gary Dubin is often cited by papers focused on Hepatitis B Virus Studies (43 papers), Cervical Cancer and HPV Research (41 papers) and Herpesvirus Infections and Treatments (19 papers). Gary Dubin collaborates with scholars based in United States, Belgium and Finland. Gary Dubin's co-authors include Anne Schuind, Cecília Roteli-Martins, Eduardo L. Franco, Diane M. Harper, David Jenkins, Cosette M. Wheeler, Barbara Romanowski, Anna‐Barbara Moscicki, Sue Ann Costa Clemens and Dominique Descamps and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Gary Dubin

74 papers receiving 8.0k citations

Hit Papers

Efficacy of a bivalent L1 virus-like particle vaccine in ... 2002 2026 2010 2018 2004 2006 2006 2002 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    2004 1.2k citations Diane M. Harper, Eduardo L. Franco et al. The Lancet profile →
  2. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    2006 1.2k citations Diane M. Harper, Eduardo L. Franco et al. The Lancet profile →
  3. ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
    2006 648 citations Gary Dubin, Geoff P. Garnett et al. profile →
  4. Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
    2002 583 citations Lawrence R. Stanberry, Spotswood L. Spruance et al. New England Journal of Medicine profile →
  5. Efficacy Results of a Trial of a Herpes Simplex Vaccine
    2012 376 citations Robert B. Belshe, Peter A. Leone et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Dubin United States 39 7.0k 2.1k 1.8k 865 749 74 8.5k
Mark T. Esser United States 43 4.6k 0.7× 1.4k 0.7× 1.5k 0.8× 1.3k 1.5× 440 0.6× 100 6.4k
Darron R. Brown United States 35 4.7k 0.7× 1.0k 0.5× 1.8k 1.0× 234 0.3× 680 0.9× 124 5.6k
Kevin A. Ault United States 36 6.2k 0.9× 1.4k 0.7× 1.8k 1.0× 682 0.8× 620 0.8× 114 9.3k
Anna‐Lise Williamson South Africa 46 4.1k 0.6× 1.4k 0.7× 1.4k 0.7× 1.1k 1.3× 709 0.9× 265 7.2k
Diane M. Harper United States 31 5.4k 0.8× 1.2k 0.6× 2.4k 1.3× 276 0.3× 2.7k 3.6× 136 8.8k
Janine T. Bryan United States 34 4.7k 0.7× 933 0.4× 2.1k 1.2× 202 0.2× 581 0.8× 67 5.7k
Anne Schuind United States 27 3.5k 0.5× 875 0.4× 1.2k 0.6× 489 0.6× 356 0.5× 76 4.4k
Adriana Weinberg United States 45 4.3k 0.6× 1.5k 0.7× 407 0.2× 1.2k 1.4× 526 0.7× 234 6.3k
Pierre Coursaget France 47 4.3k 0.6× 831 0.4× 589 0.3× 1.0k 1.2× 1.2k 1.6× 192 6.5k
Joseph B. Domachowske United States 43 3.7k 0.5× 1.5k 0.7× 724 0.4× 1.4k 1.6× 202 0.3× 172 6.0k

Countries citing papers authored by Gary Dubin

Since Specialization
Citations

This map shows the geographic impact of Gary Dubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Dubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Dubin more than expected).

Fields of papers citing papers by Gary Dubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Dubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Dubin. The network helps show where Gary Dubin may publish in the future.

Co-authorship network of co-authors of Gary Dubin

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Dubin. A scholar is included among the top collaborators of Gary Dubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Dubin. Gary Dubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vänskä, Simopekka, Tapio Luostarinen, Iacopo Baussano, et al.. (2020). Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. The Journal of Infectious Diseases. 222(6). 948–956. 37 indexed citations
2.
Schwarz, Tino F., Li‐Min Huang, Alejandra Valencia, et al.. (2019). A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Human Vaccines & Immunotherapeutics. 15(7-8). 1970–1979. 45 indexed citations
3.
Palmroth, Johanna, Tapio Luostarinen, Dan Apter, et al.. (2018). Evaluation of HPV type‐replacement in unvaccinated and vaccinated adolescent females—Post‐hoc analysis of a community‐randomized clinical trial (II). International Journal of Cancer. 142(12). 2491–2500. 30 indexed citations
4.
Ott, Mary A., Francis P. Crawley, Xavier Sáez‐Llorens, et al.. (2018). Ethical Considerations for the Participation of Children of Minor Parents in Clinical Trials. Pediatric Drugs. 20(3). 215–222. 11 indexed citations
5.
Lehtinen, Matti, Camilla Lagheden, Tapio Luostarinen, et al.. (2017). Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. BMJ Open. 7(8). e015867–e015867. 72 indexed citations
6.
Ramanakumar, Agnihotram V., Paulo Naud, Cecília Roteli-Martins, et al.. (2016). Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. BMJ Open. 6(8). e011371–e011371. 27 indexed citations
7.
Belshe, Robert B., Peter A. Leone, David I. Bernstein, et al.. (2012). Efficacy Results of a Trial of a Herpes Simplex Vaccine. New England Journal of Medicine. 366(1). 34–43. 376 indexed citations breakdown →
8.
Palmroth, Johanna, Marko Merikukka, Jorma Paavonen, et al.. (2012). Occurrence of vaccine and non‐vaccine human papillomavirus types in adolescent Finnish females 4 years post‐vaccination. International Journal of Cancer. 131(12). 2832–2838. 25 indexed citations
9.
Roteli-Martins, Cecília, Newton Sérgio de Carvalho, Paulo Naud, et al.. (2011). Prevalence of Human Papillomavirus Infection and Associated Risk Factors in Young Women in Brazil, Canada, and the United States. International Journal of Gynecological Pathology. 0(0). 173–184. 29 indexed citations
10.
Lehtinen, Matti, et al.. (2008). Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04 Adjuvanted Vaccine in Healthy Males Aged 10–18 Years. International Journal of Infectious Diseases. 12. e174–e174. 2 indexed citations
11.
Petäjä, Tiina, et al.. (2008). Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years. Journal of Adolescent Health. 44(1). 33–40. 106 indexed citations
12.
Pedersen, C, Tiina Petäjä, Gitte Strauss, et al.. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.. Journal of Child and Adolescent Mental Health. 40. 564–571. 5 indexed citations
13.
Hildesheim, Allan, Rolando Herrero, Sholom Wacholder, et al.. (2007). Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. JAMA. 298(7). 743–743. 463 indexed citations
14.
Pedersen, Court, Tiina Petäjä, Gitte Strauss, et al.. (2007). Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant. Journal of Adolescent Health. 40(6). 564–571. 192 indexed citations
15.
Harper, Diane M., Eduardo L. Franco, Cosette M. Wheeler, et al.. (2005). Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial. Obstetrical & Gynecological Survey. 60(3). 171–173. 205 indexed citations
16.
Harper, Diane M., Eduardo L. Franco, Cosette M. Wheeler, et al.. (2005). Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized, Controlled Trial. Obstetrical & Gynecological Survey. 60(5). 303–305. 12 indexed citations
17.
Harper, Diane M., Eduardo L. Franco, Cosette M. Wheeler, et al.. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet. 364(9447). 1757–1765. 1188 indexed citations breakdown →
18.
Stanberry, Lawrence R., Spotswood L. Spruance, Anthony L. Cunningham, et al.. (2002). Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes. New England Journal of Medicine. 347(21). 1652–1661. 583 indexed citations breakdown →
19.
Chernak, Esther, Gary Dubin, David W. Henry, et al.. (1995). Infection Due to Parvovirus B19 in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 20(1). 170–173. 49 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark T. Esser Breakdown of academic impact, for papers by Darron R. Brown Breakdown of academic impact, for papers by Kevin A. Ault Breakdown of academic impact, for papers by Anna‐Lise Williamson Breakdown of academic impact, for papers by Diane M. Harper Breakdown of academic impact, for papers by Janine T. Bryan Breakdown of academic impact, for papers by Anne Schuind Breakdown of academic impact, for papers by Adriana Weinberg Breakdown of academic impact, for papers by Pierre Coursaget Breakdown of academic impact, for papers by Joseph B. Domachowske
Rankless by CCL
2026